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Optimizing treatment of
seminoma stage IIA/B step by
step
We would like to congratulate Horwich et al. for their results on
therapy optimization for stage IIA/B testicular seminoma [1].
The 100% recurrence-free survival rate was achieved by the
combination of low-intensity carboplatin chemotherapy and
partially limited dose and volume radiotherapy. The key idea
behind this concept is eliminating the weaknesses of radio- and
chemotherapy, if used as single modality. While radiation
therapy is highly effective in the paraaortal and pelvic nodal
regions, relapses can occur outside the irradiated volume [2].
On the other hand, carboplatin can safely combat microscopic
tumour deposits, but it cannot achieve satisfactory remission in
the involved lymph nodes [3]. Combining both modalities each
in deescalated form can thus achieve optimal results, hopefully
without additional toxicity.
The Swiss Group for Clinical Cancer Research (SAKK)
together with the German Testicular Cancer Study Group has
embarked on a prospective trial to test one cycle carboplatin
AUC7 followed by involved node radiation therapy for stage
IIA/B seminoma patients (NCT01593241) (http://clinicaltrials.
gov/show/NCT01593241). The SAKK-01/10 trial is recruiting
patients at nine sites since 2012.
The novel approach of the trial is to further deescalate
treatment by drastically shrinking the radiation ﬁelds to
include only the involved lymph nodes and adjacent high-risk
regions. A centralized review of initial diagnostic imaging with
deﬁnition of gross tumour volume (GTV), clinical target
volume (CTV) and planning target volume (PTV) is carried
out upon study inclusion. The GTV, CTV and PTV
recommendation by the reference panel is then used by the
treating physicians for radiation therapy planning. The
resulting PTV as per SAKK-01/10 protocol in a patient with a
single affected lymph node is >80% smaller compared with the
standard PTV (paraaortal and ipsilateral pelvic lymph node
areas) for a seminoma stage IIA/B patient. We expect this
reduction in treatment volume to result in a marked difference
in the incidence of acute and late adverse events while
hopefully maintaining its efﬁcacy.
Early stage Hodgkin’s lymphoma and seminoma are similar
diseases with cure achieved in over 90% of patients with ﬁrst-
line treatment. Late treatment sequelae are a major concern,
since they may affect even more patients than disease recurrence
will. While numerous phase III trials have addressed therapy
optimization for all stages of Hodgkin’s lymphoma with practice
changing results (http://clinicaltrials.gov/show/NCT01593241),
rather little has been done prospectively in seminoma, especially
stage IIA/B. One of the problems is surely to obtain appropriate
funding for clinical research in this curable and rather rare
disease. Therefore, current stage IIA/B seminoma treatment
guidelines are based on the retrospective analyses and rather
small single-arm prospective trials.
We look forward to joining efforts with interested physicians
for collaborative trials on testicular cancer patients testing novel
treatment approaches.
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Bio-radiation dermatitis: the need
of a new grading: in regard to
Bernier et al: Ann Oncol 2011; 22
(10): 2191–2200
Dear Sir,
The Bernier [1] proposal regarding speciﬁcally the new radio-
biodermatitis classiﬁcation has so far been the only article to
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